It is important to note that torcetrapib also raised blood pressure in the mouse, which normally does not express CETP, thus strongly indicating adverse off-target effects. Torcetrapib-treated individuals in ILLUMINATE had higher mortality from sepsis and cancer. Could more comprehensive proteomics markers have offered useful insights and predictions during the early stages of the trial and averted some of the adverse events?
In the present study, Williams et al 1 aimed to determine (1) whether reasons of the harmful effects of torcetrapib could be found in the plasma profiles of ILLUMINATE participants, and (2) whether a proteinbased risk score might detect early changes in cardiovascular risk in participants treated with torcetrapib. To do so, the authors retrospectively analyzed paired plasma samples collected at baseline and at 3 months of randomized treatment from 494 ILLUMINATE participants. Within-participant changes in plasma proteins during the initial 3 months of the trial were then compared between case (encountering cardiovascular events) and control (no events) individuals among the 249 pairs of samples in the torcetrapib plus atorvastatin arm and 223 in the atorvastatin-only arm. A total of 986 proteins were quantified in 472 paired plasma samples using a modified-aptamer array method developed by scientists from SomaLogic Inc, which coauthored the study.
Aptamer-based arrays are a relative newcomer to the field of proteomics technologies currently dominated by multiplexed immunoassays and mass spectrometry. Over the past decade, the team at SomaLogic has developed a number of chemically modified nucleotide probes that bind to hand-picked protein targets. A current iteration of the commercial platform comprises ≈1100 probes, with many targeting low-abundance plasma proteins that are otherwise difficult to detect without time-consuming enrichment. The platform showed promises in recent studies both within and without the cardiovascular space. [6] [7] [8] Although aptamerbased protein quantification does not feature the same low cost of immunoassays or the unrivaled versatility and specificity of mass spectrometry, it offers an excellent trade-off between scope (number of proteins) and throughput (number of samples) and hence may be particularly well suited to targeted discovery in plasma samples from large clinical cohorts. For instance, the authors have previously quantified 1054 proteins from 938 samples in the Heart and Soul studies to derive a 9-protein marker for cardiovascular risk and then validated it in an independent set of 971 samples in the HUNT3 cohort (Helseundersøkelsen i Nord-Trøndelag). 6 Although immunoassays have high throughput and lower cost, they typically cannot monitor over a few dozen proteins, whereas mass spectrometry can monitor >10 000 proteins and posttranslational modifications but remains not routinely accessible to large clinical cohorts. Hence, these technologies will likely occupy complementary niches toward the goal of realizing multiprotein biomarker panels.
With the assays, the authors found significant changes in the plasma concentration of 200 proteins after torcetrapib treatment, including proteins in inflammation and immunity pathways, as well as proteins functioning in aldosterone pathways. 1 Changes in the aldosterone pathway are consistent with animal findings in previous studies that implicate aldosterone signaling in torcetrapib. 9 To demonstrate that the protein profiles measured correspond to cardiovascular risks in the trial participant, the authors used the 9-protein risk score they previously established and calculated the risks in each of the case and control groups without further recalibrating the biomarker panel. They showed that torcetrapib treatment led to a net increase of cardiovascular events of 1.08% over all individuals-1.55% in cases versus 0.52% in controls. This compares to the actual increase in cardiovascular events in the torcetrapib treatment arm (1.2%) and stands in contrast to the treatment's associated decrease in absolute Framingham risk (-1.5%).
The authors identified potential deleterious mechanisms of torcetrapib from the plasma protein profiles. These data are particularly intriguing and underscore the power of proteomics to reveal dynamic changes in response to external stimuli. Unlike genetic profiles, proteins in the plasma can alter at multiple time points before, during, and after drug exposure and can further reflect the status of multiple systems in the body. Remarkably, the increase in cardiovascular risk based on proteomic analysis was already apparent just 3 months into the trial, preceding the onset of the majority of clinical events by a healthy margin. Although in hindsight the potential of torcetrapib to cause harm was also discovered in subsequent imaging and blood pressure analysis, this was critically not reflected in the Framingham risk score because the decrease in bad cholesterol was thought to outweigh the potential deleterious effects of blood pressure. Many of the altered proteins after torcetrapib changed in the same direction as those indicating increased risks in the Heart and Soul cohort, from which the 9-protein risk score was originally derived. This finding suggests that concerted changes in plasma protein profile may be a feature of elevated cardiovascular risks, which requires large-scale analysis to distinguish.
The present work prompts fresh questions. For instance, it remains inconclusive whether the failure of torcetrapib was a result of CETP inhibition, off-target effects, or a combination of the two. Application of proteomics technology to other CETP inhibitors may therefore be instructive. Moreover, the mechanism behind the enrichment of immunity and inflammation proteins remains to be elucidated. Given that the human plasma contains an admixture of proteins originating from numerous cells and tissues in the body, it will be intriguing to find out whether circulating blood cells are primarily responsible for the plasma protein profiles or are particular foci of lesions in the body from which the molecules originated. Because the aptamer assays used here monitored selected proteins, further clues into mechanisms will likely require deeper investigations into regulatory proteins, pathways, and post-translational modifications in relevant pathways not assessed here.
Nevertheless, the present work demonstrates how proteomics can contribute to safer and more informative trials in the future. With continual development and lowering costs of proteomics technologies, future trials will likely be routinely embedded with longitudinal proteomics profiling to enhance participant safety and inform drug assessment (Figure) . The present study does not explicitly calculate individual risks. Hence, more work is needed to determine whether the predicted harm from the protein risk score would have presented sufficient cause of concern to terminate the trial before cardiovascular events occurred. It should, of course, be offered as a caution that the reliance on a surrogate marker (ie, HDL) associated with the actual outcome of interest was a major motivation behind the development of CETP inhibitors in the first place. Therefore, a particularly important lesson learned from this study is that although some individual markers may go against the trend of risks, this may be circumventable by more comprehensive panels considering multiple molecules in unison and the deployment of large-scale studies, which are unbiased to singular molecules or pathways. With the rapid evolution of proteomics technologies from multiple fronts, we can look forward to ever more comprehensive insights into the dynamic profiles of plasma proteins, isoforms, and protein posttranslational modifications from participants in clinical trials. 
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Figure. Embedding proteomics profiling to assess drug safety and efficacy.
Enabled by continuous development of proteomics technology, future clinical trials can be envisioned where the dynamic plasma profiles of participants may be profiled longitudinally to help assess risks and provide insights into drug mechanisms.
